Lifecore Biomedical Inc. (LFCR) - Net Assets
Based on the latest financial reports, Lifecore Biomedical Inc. (LFCR) has net assets worth $20.78 Million USD as of February 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($225.50 Million) and total liabilities ($204.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore LFCR operating cash flow to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.78 Million |
| % of Total Assets | 9.21% |
| Annual Growth Rate | -10.79% |
| 5-Year Change | -99.34% |
| 10-Year Change | -99.37% |
| Growth Volatility | 30.75 |
Lifecore Biomedical Inc. - Net Assets Trend (1996–2025)
This chart illustrates how Lifecore Biomedical Inc.'s net assets have evolved over time, based on quarterly financial data. Explore LFCR long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Net Assets for Lifecore Biomedical Inc. (1996–2025)
The table below shows the annual net assets of Lifecore Biomedical Inc. from 1996 to 2025. For live valuation and market cap data, see LFCR company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-05-31 | $1.34 Million | -88.19% |
| 2024-05-31 | $11.31 Million | -87.12% |
| 2023-05-31 | $87.82 Million | -18.64% |
| 2022-05-31 | $107.94 Million | -46.77% |
| 2021-05-31 | $202.78 Million | -12.23% |
| 2020-05-31 | $231.04 Million | -14.47% |
| 2019-05-31 | $270.14 Million | +6.96% |
| 2018-05-31 | $252.56 Million | +10.70% |
| 2017-05-31 | $228.15 Million | +7.44% |
| 2016-05-31 | $212.35 Million | -3.53% |
| 2015-05-31 | $220.11 Million | +7.50% |
| 2014-05-31 | $204.76 Million | +13.50% |
| 2013-05-31 | $180.41 Million | +19.04% |
| 2012-05-31 | $151.56 Million | +10.04% |
| 2011-05-31 | $137.73 Million | +3.96% |
| 2010-05-31 | $132.47 Million | +4.15% |
| 2009-05-31 | $127.20 Million | +9.64% |
| 2008-05-31 | $116.02 Million | +3.52% |
| 2007-05-31 | $112.07 Million | +29.09% |
| 2006-05-31 | $86.82 Million | +18.08% |
| 2005-05-31 | $73.53 Million | +16.52% |
| 2004-05-31 | $63.10 Million | +5.87% |
| 2003-05-31 | $59.60 Million | +3.58% |
| 2002-05-31 | $57.54 Million | +13.11% |
| 2001-05-31 | $50.87 Million | -10.74% |
| 2000-05-31 | $57.00 Million | +79.24% |
| 1999-05-31 | $31.80 Million | -5.64% |
| 1998-05-31 | $33.70 Million | -5.34% |
| 1997-05-31 | $35.60 Million | -2.73% |
| 1996-05-31 | $36.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lifecore Biomedical Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17394000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (May 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.00K | 2.77% |
| Other Components | $206.54 Million | 15459.51% |
| Total Equity | $1.34 Million | 100.00% |
Lifecore Biomedical Inc. Competitors by Market Cap
The table below lists competitors of Lifecore Biomedical Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GTM Holdings Corp
TW:1437
|
$179.67 Million |
|
Lanson BCC SA
PA:ALLAN
|
$179.70 Million |
|
Healius Ltd
AU:HLS
|
$179.83 Million |
|
Sukgyung AT Co. Ltd.
KQ:357550
|
$179.87 Million |
|
Shandong Molong Petroleum Machinery Company Limited
F:PXI
|
$179.66 Million |
|
Eaton Vance New York MBF
NYSE MKT:ENX
|
$179.61 Million |
|
GD Express Carrier Bhd
KLSE:0078
|
$179.61 Million |
|
Lealea Enterprise Co Ltd
TW:1444
|
$179.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lifecore Biomedical Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,315,000 to 1,336,000, a change of -9,979,000 (-88.2%).
- Net loss of 38,717,000 reduced equity.
- New share issuances of 23,850,000 increased equity.
- Other comprehensive income increased equity by 42,587,000.
- Other factors decreased equity by 37,699,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.72 Million | -2897.98% |
| Share Issuances | $23.85 Million | +1785.18% |
| Other Comprehensive Income | $42.59 Million | +3187.65% |
| Other Changes | $-37.70 Million | -2821.78% |
| Total Change | $- | -88.19% |
Book Value vs Market Value Analysis
This analysis compares Lifecore Biomedical Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 125.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.03x to 125.62x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-05-31 | $4.68 | $4.82 | x |
| 1997-05-31 | $3.19 | $4.82 | x |
| 1998-05-31 | $2.53 | $4.82 | x |
| 1999-05-31 | $3.18 | $4.82 | x |
| 2000-05-31 | $3.54 | $4.82 | x |
| 2001-05-31 | $3.04 | $4.82 | x |
| 2002-05-31 | $3.08 | $4.82 | x |
| 2003-05-31 | $2.49 | $4.82 | x |
| 2004-05-31 | $2.61 | $4.82 | x |
| 2005-05-31 | $2.93 | $4.82 | x |
| 2006-05-31 | $3.31 | $4.82 | x |
| 2007-05-31 | $4.15 | $4.82 | x |
| 2008-05-31 | $4.25 | $4.82 | x |
| 2009-05-31 | $4.75 | $4.82 | x |
| 2010-05-31 | $4.91 | $4.82 | x |
| 2011-05-31 | $5.11 | $4.82 | x |
| 2012-05-31 | $5.73 | $4.82 | x |
| 2013-05-31 | $6.71 | $4.82 | x |
| 2014-05-31 | $7.49 | $4.82 | x |
| 2015-05-31 | $7.99 | $4.82 | x |
| 2016-05-31 | $7.76 | $4.82 | x |
| 2017-05-31 | $8.20 | $4.82 | x |
| 2018-05-31 | $9.05 | $4.82 | x |
| 2019-05-31 | $9.44 | $4.82 | x |
| 2020-05-31 | $7.92 | $4.82 | x |
| 2021-05-31 | $6.92 | $4.82 | x |
| 2022-05-31 | $3.66 | $4.82 | x |
| 2023-05-31 | $2.98 | $4.82 | x |
| 2024-05-31 | $0.31 | $4.82 | x |
| 2025-05-31 | $0.04 | $4.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lifecore Biomedical Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2897.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -30.04%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 179.15x
- Recent ROE (-2897.98%) is below the historical average (-104.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -11.48% | -168.00% | 0.07x | 1.05x | $-7.86 Million |
| 1997 | -24.16% | -90.53% | 0.19x | 1.41x | $-12.16 Million |
| 1998 | -8.61% | -8.66% | 0.79x | 1.26x | $-6.27 Million |
| 1999 | -8.81% | -7.91% | 0.87x | 1.28x | $-5.98 Million |
| 2000 | -7.16% | -1.91% | 1.69x | 2.22x | $-9.58 Million |
| 2001 | -37.70% | -9.84% | 1.59x | 2.41x | $-23.77 Million |
| 2002 | -2.66% | -0.81% | 1.70x | 1.93x | $-7.08 Million |
| 2004 | 4.71% | 1.51% | 2.07x | 1.51x | $-3.25 Million |
| 2005 | 7.50% | 2.63% | 2.05x | 1.39x | $-1.80 Million |
| 2006 | 10.17% | 3.73% | 1.95x | 1.40x | $146.10K |
| 2007 | 26.48% | 13.87% | 1.49x | 1.28x | $18.17 Million |
| 2008 | 11.83% | 5.68% | 1.58x | 1.32x | $2.10 Million |
| 2009 | 6.08% | 3.28% | 1.54x | 1.20x | $-4.99 Million |
| 2010 | 3.05% | 1.67% | 1.19x | 1.53x | $-9.09 Million |
| 2011 | 2.88% | 1.42% | 1.34x | 1.52x | $-9.69 Million |
| 2012 | 8.48% | 4.00% | 1.14x | 1.85x | $-2.28 Million |
| 2013 | 12.64% | 5.11% | 1.52x | 1.63x | $4.72 Million |
| 2014 | 9.43% | 4.02% | 1.52x | 1.54x | $-1.16 Million |
| 2015 | 6.20% | 2.51% | 1.56x | 1.59x | $-8.30 Million |
| 2016 | -5.52% | -2.15% | 1.58x | 1.63x | $-32.71 Million |
| 2017 | 4.67% | 1.99% | 1.49x | 1.58x | $-12.07 Million |
| 2018 | 9.83% | 4.74% | 1.30x | 1.60x | $-427.20K |
| 2019 | 0.79% | 0.38% | 1.07x | 1.92x | $-24.89 Million |
| 2020 | -16.53% | -23.86% | 0.30x | 2.34x | $-61.30 Million |
| 2021 | -15.93% | -32.01% | 0.20x | 2.48x | $-52.57 Million |
| 2022 | -90.26% | -52.44% | 0.63x | 2.73x | $-108.23 Million |
| 2023 | -132.90% | -104.89% | 0.41x | 3.13x | $-125.50 Million |
| 2024 | 106.17% | 9.37% | 0.51x | 22.44x | $10.88 Million |
| 2025 | -2897.98% | -30.04% | 0.54x | 179.15x | $-38.85 Million |
Industry Comparison
This section compares Lifecore Biomedical Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $635,904,067
- Average return on equity (ROE) among peers: -3.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lifecore Biomedical Inc. (LFCR) | $20.78 Million | -11.48% | 9.85x | $179.67 Million |
| Aurora Cannabis Inc (ACB) | $4.40 Billion | -6.66% | 0.28x | $201.62 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $11.58 Million |
| Akebia Ther (AKBA) | $-30.58 Million | 0.00% | 0.00x | $275.92 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $5.83 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.56 Billion |
| Amphastar P (AMPH) | $528.66 Million | 17.29% | 0.40x | $837.77 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-186.87 Million | 0.00% | 0.00x | $4.08 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-175.94 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.80 Million | -34.48% | 0.38x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $174.76 Million | -0.62% | 1.36x | $1.80 Billion |
About Lifecore Biomedical Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more